Last $45.50 USD
Change Today -0.43 / -0.94%
Volume 934.1K
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

intermune inc (ITMN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/14 - $47.72
52 Week Low
02/5/14 - $10.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INTERMUNE INC (ITMN)

intermune inc (ITMN) Related Businessweek News

No Related Businessweek News Found

intermune inc (ITMN) Details

InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases in North America and Europe. The company develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, and fatal lung disease. It markets and sells pirfenidone, an orally active, anti-fibrotic agent that inhibits the synthesis of TGF-beta and TNF-alpha under the Esbriet name for the treatment of adults with mild to moderate IPF in the European Union and Canada. The company’s pirfenidone has also completed three Phase III clinical trials for the treatment of IPF in the United States. The company provides pirfenidone under the Pirespa trade name for the treatment of IPF in Japan and South Korea; and is also approved for the treatment of IPF in China, India, Argentina, and Mexico. Its research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was formerly known as InterMune Pharmaceuticals, Inc. and changed its name to InterMune, Inc. in April 2001. InterMune, Inc. was founded in 1998 and is headquartered in Brisbane, California.

364 Employees
Last Reported Date: 05/2/14
Founded in 1998

intermune inc (ITMN) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $703.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $412.0K
Executive Vice President and Managing Directo...
Total Annual Compensation: $439.5K
Chief Business Officer and Executive Vice Pre...
Total Annual Compensation: $380.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $196.9K
Compensation as of Fiscal Year 2013.

intermune inc (ITMN) Key Developments

InterMune Receives FDA Breakthough Therapy Designation for Pirfenidone, an Investigational Treatment for IPF

InterMune, Inc. announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. As described in the FDA Fact Sheet: Breakthrough Therapies, 'If a drug is designated as breakthrough therapy, FDA will expedite the development and review of such drug'.

InterMune, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 02:30 PM

InterMune, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 02:30 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States.

InterMune, Inc. Announces Resubmission of NDA for Pirfenidone for the Treatment of Patients with IPF

InterMune, Inc. announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). Under the Prescription Drug User Fee Act (PDUFA), the FDA has 74 days after receipt of an NDA to evaluate the submission in order to determine if it is sufficiently complete. If in this 74-day period the FDA determines that the submission is complete, the review clock will be deemed to have started as of the date that the resubmission was initially received by the FDA. As the resubmission of an efficacy supplement, the submission of the ASCEND data represents a Class 2 resubmission that has a target FDA review of six months under PDUFA V. In May 2010, InterMune received a CRL from the FDA. In the CRL, the FDA recommended an additional Phase 3 clinical trial to support the efficacy of pirfenidone. Since the receipt of the CRL, InterMune has conducted the Phase 3 ASCEND trial of pirfenidone in IPF, and results of that trial were presented on May 18, 2014, at the meeting of the American Thoracic Society and were published on-line the same day in the New England Journal of Medicine. The NDA resubmission includes the ASCEND Clinical Study Report as well as the pooled analyses of efficacy and mortality from the three InterMune Phase 3 trials: ASCEND and the previous Phase 3 CAPACITY trials (004 and 006). Additionally, the NDA resubmission includes a safety update of approximately 15,000 patients including clinical studies and the extensive post-marketing experience of pirfenidone collected since 2008.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ITMN:US $45.50 USD -0.43

ITMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $5.89 USD -0.293
Array BioPharma Inc $4.18 USD -0.10
Medivation Inc $75.79 USD +0.33
Seattle Genetics Inc $34.89 USD +0.20
Spectrum Pharmaceuticals Inc $7.05 USD -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation ITMN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 45.8x
Price/Book 12.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERMUNE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at